Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conference

October 26-31, 2020 | Virtual Global Conference

Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty,  R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell

In the last week of October, consultants and specialist psychologists, nurses, scientists and…

Read more

15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conference

October 26-31, 2020 | Virtual Global Conference

Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty,  R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell

In the last week of October, consultants and specialist psychologists, nurses, scientists and…

Read more

EHA and PTHiT Successfully Conclude the Second Joint Virtual Mini Hematology Tutorial

EHA-PTHiT Mini Hematology Tutorial

November 15-16, 2021

Meeting chairs:

Prof G Gaidano (European Hematology Association)
Prof I Hus (Polish Society of Hematology and Transfusion)
Prof T Robak (Polish Society of Hematology and Transfusion) 
After a successful mini Tutorial in April 2021, EHA and PTHiT decided to…

Read more

Rebuilding the future for hematology in Ukraine today

The Hague (Netherlands), December 5, 2022 - Nearly 8 million Ukrainians have fled their country since February 24 according to the UN Refugee Agency, while about 5 million people have moved back.

Read more

Wiley and European Hematology Association Announce Partnership

Wiley will publish HemaSphere beginning January 2024

Hoboken, NJ, (USA) and The Hague (Netherlands) – Wiley, one of the world’s largest publishers and a global leader in research and education, today announced that it will publish the open access journal HemaSphere on…

Read more